New specialty pharma company holds promise of innovative drug development

(San Francisco, CA) April 30, 2010 – TesoRx Pharma, LLC., a California-based pharmaceutical company, announced its recent formation by Dr. Ramachandran “TR” Thirucote, a well-known pharma personality from Silicon Valley.

Dr. Thirucote has extensive hands-on experience in the design and development of various dosage forms spanning 30 years. Most recently, he was Vice President, Pharmaceutical Sciences at Roxro Pharma, Inc.. During his tenure, he was responsible for developing SprixTM and obtaining FDA approval in May of 2010. Dr. Thirucote is a reputed scientist, inventor and celebrated speaker who will take the role of CEO in the new enterprise.

“There are numerous products that are not being developed even though they are efficacious, safe and can address very clear market needs. We are creating a company that will pursue the licensing of such compounds and that will develop them so they can be exploited commercially.” said Dr. Thirucote.

TesoRx has a pipeline of opportunities and will be seeking Series A funding soon. 


About TesoRx

TesoRx Pharma LLC is focused on rapidly developing and commercializing pharmaceutical products in rare and specialty markets with limited treatment options and high unmet need. Its growing pipeline includes assets in urology, oncology and rare diseases that have been formulated with TesoRx’s proprietary proliposomal delivery technology. The company was founded in 2010 through a collaboration with Western University of Health Sciences that includes joint R&D efforts at the TesoRx Centre of Excellence in Pomona, California.  More information at www.tesorx.com

More information at www.tesorx.com
Binay Curtis, Galaxy Six Strategies Public Relations: Binay@galaxysix.com